thyronines has been researched along with Polycystic-Ovary-Syndrome* in 2 studies
2 other study(ies) available for thyronines and Polycystic-Ovary-Syndrome
| Article | Year |
|---|---|
Metabolic profiling reveals reprogramming of lipid metabolic pathways in treatment of polycystic ovary syndrome with 3-iodothyronamine.
Complex diseases such as polycystic ovary syndrome (PCOS) are associated with intricate pathophysiological, hormonal, and metabolic feedbacks that make their early diagnosis challenging, thus increasing the prevalence risks for obesity, cardiovascular, and fatty liver diseases. To explore the crosstalk between endocrine and lipid metabolic pathways, we administered 3-iodothyronamine (T1AM), a natural analog of thyroid hormone, in a mouse model of PCOS and analyzed plasma and tissue extracts using multidisciplinary omics and biochemical approaches. T1AM administration induces a profound tissue-specific antilipogenic effect in liver and muscle by lowering gene expression of key regulators of lipid metabolism, PTP1B and PLIN2, significantly increasing metabolites (glucogenic, amino acids, carnitine, and citrate) levels, while enhancing protection against oxidative stress. In contrast, T1AM has an opposing effect on the regulation of estrogenic pathways in the ovary by upregulating STAR, CYP11A1, and CYP17A1. Biochemical measurements provide further evidence of significant reduction in liver cholesterol and triglycerides in post-T1AM treatment. Our results shed light onto tissue-specific metabolic vs. hormonal pathway interactions, thus illuminating the intricacies within the pathophysiology of PCOS This study opens up new avenues to design drugs for targeted therapeutics to improve quality of life in complex metabolic diseases. Topics: Animals; Cholesterol; Female; Gene Expression; Lipid Metabolism; Liver; Magnetic Resonance Spectroscopy; Metabolic Networks and Pathways; Metabolomics; Mice; Muscles; Obesity; Ovary; Oxidative Stress; Polycystic Ovary Syndrome; Quality of Life; Thyronines; Triglycerides | 2017 |
[Therapy of female hirsutism: current status and new findings].
Topics: Adrenal Cortex Hormones; Adrenal Hyperplasia, Congenital; Androgen Antagonists; Androgens; Bromocriptine; Cimetidine; Cyproterone; Cyproterone Acetate; Drug Combinations; Estradiol Congeners; Female; Hirsutism; Humans; Polycystic Ovary Syndrome; Progesterone Congeners; Spironolactone; Thyronines; Time Factors | 1983 |